Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.11.1.7 (peroxidase)
 65,474 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Effects of bumetanide on in vitro bilirubin binding to albumin were studied in pooled sera of critically ill neonates using the hydroxybenzeneazobenzoic acid (HBABA) dye binding method and the horseradish peroxidase assay. Mean HBABA dye binding capacity decreased significantly from 63.75 +/- 5.9% in the absence of drug to 50.8 +/- 6.7% and 44.6 +/- 6.3% with concentrations of 0.25 and 50 micrograms/ml, respectively (p less than 0.005). Bumetanide caused an increase in unbound bilirubin concentration at drug concentrations of 0.5-50 micrograms/ml. Bumetanide is a potent displacer of bilirubin and should be used with caution in jaundiced neonates.
 ...
PMID:The bilirubin-displacing capacity of bumetanide in critically ill neonates. 319 18

Bumetanide binding to human serum albumin was studied using ultrafiltration. The first stoichiometric binding constant for bumetanide is 6.4 X 10(4) M-1. Bumetanide competes with bilirubin for human serum albumin binding, having a KDispl (displacement constant) of 6.2 X 10(3) M-1 measured by the peroxidase method. This displacement effect is also observed using pooled umbilical cord serum and pooled adult serum employing a dialysis rate method. Bumetanide competes to a lesser degree with diazepam binding to human serum albumin. No competition with diazepam occurs using umbilical cord or adult serum. Pharmacologic concentrations of bumetanide would not significantly affect bilirubin-albumin binding and should not increase the risk of bilirubin encephalopathy in newborn infants.
 ...
PMID:Albumin binding of bumetanide. 375 31

The effect of loop diuretics at concentrations known to influence cellular water entry coupled to Na-K-Cl co-transport, upon the vacuolation and detubulation following osmotic shock, was investigated in amphibian skeletal muscles. These were exposed to a glycerol-Ringer solution (18 min), an isotonic Ca2+/Mg2+ Ringer solution and cooling. Adding bumetanide (1.0 and 2.0 microM) to these solutions sharply reduced the incidence of detubulation, assessed by abolition or otherwise of action potential after-depolarisations, from 93.9 +/- 4.7% (n = 6) to 5.0 +/- 1.1% (n = 4: mean +/- SEM: 2.0 microM bumetanide). It dramatically reduced the number and fraction of muscle volume occupied by tubular vacuoles, measured using confocal microscopy, from 60.3 +/- 4.3% (n = 10) to 9.0 +/- 1.1% (n = 35). The incidence of large horseradish peroxidase-lined tubular vacuoles, viewed using electronmicroscopy, similarly was reduced with 2 microM bumetanide in the glycerol-Ringer solution. Bumetanide acted through cellular volume adjustments early in the detubulation protocol. Thus, it exerted its maximum effect when added to the glycerol-Ringer, rather than the Ca2+/Mg2+ Ringer solution. Furthermore, whereas fibre diameters measured using scanning electron microscopy returned to normal during glycerol treatment relative to those of control fibres left in isotonic Ringer, addition of 2.0 microM bumetanide in the glycerol Ringer left markedly smaller fibre diameters. Finally equipotent concentrations of the chemically distinct loop diuretics. furosemide and ethacrynic acid similarly influenced detubulation. These findings implicate Na-K-Cl co-transport in the water entry into muscle fibres that would be expected following introduction of extracellular glycerol. This might then enable the subsequent Na-K-ATPase dependent water extrusion that produces the tubular distension (vacuolation) and detachment (detubulation) following glycerol withdrawal, phenomena also observed in muscular dystrophy.
 ...
PMID:Loop diuretics inhibit detubulation and vacuolation in amphibian muscle fibres exposed to osmotic shock. 1081 37